| Trial # | Type | Study Status | Status Date | Title |
|---|
| ASCO TAPUR | Advanced Solid Tumors | Open Active | 2021-10-20 | ASCO TAPUR: Targeted Agent and Profiling Utilization Registry (TAPUR) Study |
| INST DARE | Breast Advanced | Open Active | 2021-08-10 | INST DARE: CRITERIUM Inc., Academic Breast Cancer Consortium DARE: A randomized, phase II trial of circulating tumor DNA-guided second line adjuvant therapy for high residual risk, stage II-III, estrogen receptor positive, HER2 negative breast cancer (DARE) |
| INST University of Arizona 1807 | Breast Advanced | Open Active | 2020-02-17 | INST University of Arizona 1807: A Randomized Phase II Study to Evaluate Efficacy of T-DM1 with or without Palbociclib in the Treatment of Patients with Metastatic HER2 Positive Breast Cancer |
| CCTG MA.39 | Breast Neoadjuvant | Open Active | 2018-08-21 | CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer |
| ECOG-Acrin EA1181 | Breast Neoadjuvant | Open Active | 2022-02-17 | EA1181: The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer) |
| SWOG S1706 | Breast Neoadjuvant | Open Active | 2021-10-29 | SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer |
| SWOG S1703 | Breast Other | Open Active | 2020-04-28 | SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer |
| SWOG S1912CD | Breast Other | Open Active | 2022-12-16 | SWOG S1912CD: A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery Of A Proactive Financial Navigation Intervention (CREDIT) |
| Alliance A021502 | GI Colorectal Adjuvant | Open Active | 2022-11-16 | Alliance A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair |
| NRG-GI008 | GI Colorectal Adjuvant | Open Active | 2022-08-19 | NRG Oncology NRG-GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease |
| NRG Oncology/SWOG NRG-GI004/SWOG-S1610 | GI Colorectal Advanced | Open Active | 2021-06-28 | NRG Oncology/SWOG NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer |
| NRG-GI005 | GI Other | Open Active | 2021-06-22 | NRG-GI005: Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA) |
| Alliance A032001 | GU Ureter Advanced | Open Active | 2023-02-20 | Alliance A032001 MAIN-CAV: Phase III Randomized Trial Of Maintenance Cabozantinib And Avelumab Vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy In Patients With Metastatic Urothelial Cancer |
| GOG 0263 | GYN Cervical Adjuvant | Open Active | 2011-02-07 | GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy |
| NRG-GY023 | GYN Ovarian Advanced | Open Active | 2022-03-28 | NRG Oncology NRG-GY023: A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab |
| ECOG-ACRIN EA3202 | Head And Neck Advanced | Open Active | 2023-03-07 | ECOG-ACRIN EA3202: A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers |
| SWOG S1925 | Hematology Chronic Leukemia | Open Active | 2023-02-03 | SWOG S1925: Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study |
| ECOG-ACRIN NHLBI-MDS | Hematology Other | Open Active | 2020-05-18 | ECOG-ACRIN NHLBI-MDS: THE NATIONAL MDS STUDY A Prospective, Multi-Center Cohort Supporting Research Studies in MDS Natural History |
| Alliance A151216 | Lung NSCLC Adjuvant | Open Active | 2016-04-21 | Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) |
| ECOG-ACRIN E4512 | Lung NSCLC Adjuvant | Open Active | 2019-03-01 | ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein |
| SWOG LungMAP | Lung NSCLC Advanced | Open Active | 2019-03-26 | SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study) |
| DCP-001 | Supportive | Open Active | 2017-05-24 | DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP) |
| DCP-001A | Supportive | Open Active | 2017-05-24 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
| DCP-001B | Supportive | Open Active | 2017-05-24 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
| DCP-001C | Supportive | Open Active | 2017-05-24 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
| DCP-001D | Supportive | Open Active | 2017-05-24 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
| Trial # | Type | Study Status | Status Date | Title |
|---|
| ASCO TAPUR | Advanced Solid Tumors | Open Active | 2021-10-20 | ASCO TAPUR: Targeted Agent and Profiling Utilization Registry (TAPUR) Study |
| Alliance A011202 | Breast Adjuvant | Open Active | 2020-05-27 | Alliance A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy |
| Alliance A011801 | Breast Adjuvant | Open Active | 2021-05-17 | Alliance A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib |
| INST DARE | Breast Advanced | Open Active | 2021-12-06 | INST DARE: CRITERIUM Inc., Academic Breast Cancer Consortium DARE: A randomized, phase II trial of circulating tumor DNA-guided second line adjuvant therapy for high residual risk, stage II-III, estrogen receptor positive, HER2 negative breast cancer (DARE) |
| SWOG S1703 | Breast Other | Open Active | 2020-03-02 | SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer |
| Alliance A021502 | GI Colorectal Adjuvant | Open Active | 2022-11-16 | Alliance A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair |
| NRG-GI008 | GI Colorectal Adjuvant | Open Active | 2022-08-19 | NRG Oncology NRG-GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease |
| NRG Oncology/SWOG NRG-GI004/SWOG-S1610 | GI Colorectal Advanced | Open Active | 2021-06-28 | NRG Oncology/SWOG NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer |
| Alliance A021602 | GI Other | Open Active | 2020-12-03 | Alliance A021602: Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus (CABINET) |
| NRG-GI005 | GI Other | Open Active | 2021-06-22 | NRG-GI005: Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA) |
| NRG-GU009 | GU Other | Open Active | 2022-10-05 | NRG Oncology NRG-GU009: Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT) |
| ALLIANCE A031902 | GU Prostate Adjuvant | Open Active | 2022-05-25 | Alliance A031902: CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-resistant Prostate Cancer |
| NRG-GU010 | GU Prostate Neoadjuvant | Open Active | 2022-10-05 | NRG Oncology NRG-GU010: Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE) |
| GOG 0263 | GYN Cervical Adjuvant | Open Active | 2018-06-07 | GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy |
| NRG-GY026 | GYN Endometrial Neoadjuvant | Open Active | 2022-11-22 | NRG-GY026: A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab Trastuzumab and Hyaluronidase-Zzfx (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma |
| NRG-GY023 | GYN Ovarian Advanced | Open Active | 2022-03-28 | NRG Oncology NRG-GY023: A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab |
| SWOG S1925 | Hematology Chronic Leukemia | Open Active | 2023-02-09 | SWOG S1925: Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study |
| Alliance A151216 | Lung NSCLC Adjuvant | Open Active | 2016-08-04 | Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) |
| ECOG-ACRIN EA6141 | Skin Melanoma Advanced | Open Active | 2021-04-05 | ECOG-ACRIN EA6141: Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma |
| DCP-001 | Supportive | Open Active | 2023-01-04 | DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP) |
| Trial # | Type | Study Status | Status Date | Title |
|---|
| ASCO TAPUR | Advanced Solid Tumors | Open Active | 2021-10-20 | ASCO TAPUR: Targeted Agent and Profiling Utilization Registry (TAPUR) Study |
| Pharm BO41932 | Advanced Solid Tumors | Open Active | 2021-03-30 | Roche BO41932: Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational For You (TAPISTRY) Phase II Platform Trial |
| Pharm LNS-101 | Advanced Solid Tumors | Open Active | 2019-10-11 | Linnaeus Therapeutics LNS-101: A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab |
| Alliance A071401 | Brain Advanced | Open Active | 2022-01-14 | Alliance A071401: Phase II Trial of SMO/ AKT/ NF2 Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2 Mutations |
| Alliance A071801 | Brain Advanced | Open Active | 2020-06-11 | Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease |
| NCCTG N0577 | Brain Advanced | Open Active | 2017-12-18 | NCCTG N0577: Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma |
| NRG-BN011 | Brain Advanced | Open Active | 2022-05-17 | (Closed to IRB) NRG Oncology NRG-BN011: A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma |
| NRG Oncology NRG-BN003 | Brain Other | Open Active | 2017-10-20 | NRG Oncology NRG-BN003: Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma |
| Alliance A011801 | Breast Adjuvant | Open Active | 2021-05-17 | Alliance A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib |
| INST UNM 2004 | Breast Adjuvant | Open Active | 2022-05-27 | INST UNM 2004: Patient Understanding of the Benefit of Adjuvant Endocrine Therapy in Breast Cancer |
| ECOG-ACRIN EA1183 | Breast Advanced | Open Active | 2020-10-19 | ECOG-ACRIN EA1183: FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE |
| INST DARE | Breast Advanced | Open Active | 2021-08-09 | INST DARE: CRITERIUM Inc., Academic Breast Cancer Consortium DARE: A randomized, phase II trial of circulating tumor DNA-guided second line adjuvant therapy for high residual risk, stage II-III, estrogen receptor positive, HER2 negative breast cancer (DARE) |
| Pharm GSK 213831 | Breast Advanced | Open Active | 2023-02-14 | GlaxoSmithKline GSK 213831: A Randomized Phase 3 Double-Blinded Study Comparing Efficacy of Niraparib to Placebo in Participants with Either Triple-Negative Breast Cancer or HER2-Negative BRCA-Mutated Breast Cancer with Molecular Disease Based on Presence of Circulating Tumor DNA after Definitive Therapy |
| Pharm I3Y-MC-JPEF | Breast Advanced | Open Active | 2022-07-29 | Eli Lilly & Co. I3Y-MC-JPEF: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy |
| Pharm SGNLVA-002 | Breast Advanced | Open Active | 2022-03-31 | Seattle Genetics SGNLVA-002: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer |
| SWOG S1501 | Breast Advanced | Open Active | 2020-11-20 | SWOG S1501: Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III |
| SWOG S2007 | Breast Advanced | Open Active | 2021-09-20 | SWOG S2007: A Phase II Trial Of Sacituzumab Govitecan (IMMU-132) (NSC #820016) For Patients With HER2-Negative Breast Cancer and Brain Metastases |
| CCTG MA.39 | Breast Neoadjuvant | Open Active | 2018-09-05 | CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer |
| ECOG-Acrin EA1181 | Breast Neoadjuvant | Open Active | 2022-02-17 | EA1181: The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer) |
| NRG-BR007 | Breast Neoadjuvant | Open Active | 2021-10-29 | NRG Oncology NRG-BR007: A Phase III Clinical Trial evaluating de-escalation of Breast Radiation for conservative treatment of Stage I, hormone sensitive, HER2-Negative, Oncotype recurrence score = 18 Breast Cancer |
| SWOG S1706 | Breast Neoadjuvant | Open Active | 2021-10-29 | SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer |
| ECOG-ACRIN EA1151 | Breast Other | Open Active | 2018-08-31 | ECOG-ACRIN EA1151: Tomosynthesis Mammography Imaging Screening Trial (TMIST) |
| ECOG-ACRIN EA1151 | Breast Other | Open Active | 2022-09-29 | ECOG-ACRIN EA1151: Tomosynthesis Mammography Imaging Screening Trial (TMIST) |
| SWOG S1703 | Breast Other | Open Active | 2020-03-02 | SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer |
| SWOG S1912CD | Breast Other | Open Active | 2021-11-11 | SWOG S1912CD: A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery Of A Proactive Financial Navigation Intervention (CREDIT) |
| SWOG S1912CD | Breast Other | Open Active | 2023-01-18 | SWOG S1912CD: A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery Of A Proactive Financial Navigation Intervention (CREDIT) |
| CIBMTR Protocol for a Research Database | Epidemiological | Open Active | 2017-06-29 | CIBMTR Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries |
| CIBMTR Protocol for a Research Database | Epidemiological | Open Active | 2020-11-10 | CIBMTR Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries |
| UNM 1803 | Epidemiological | Open Active | 2018-06-26 | INST UNM 1803: Enhancing Cancer Prevention and Control Pathways in the Zuni Pueblo-Native Health Initiative |
| UNM TCCP | Epidemiological | Open Active | 2017-12-08 | INST UNM 1521: Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer |
| NRG-GI008 | GI Colorectal Adjuvant | Open Active | 2022-08-19 | NRG Oncology NRG-GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease |
| NRG Oncology/SWOG NRG-GI004/SWOG-S1610 | GI Colorectal Advanced | Open Active | 2021-06-28 | NRG Oncology/SWOG NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer |
| INST UNM 1809 | GI Colorectal Prevention | Open Active | 2018-12-27 | INST UNM 1809: Dissemination of a Colorectal Cancer Screening Program Across American Indian Communities in the Southern Plains & Southwest United States |
| SWOG S0820 | GI Colorectal Prevention | Open Active | 2017-10-05 | SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) |
| ECOG-ACRIN EA2174 | GI Esophageal Neoadjuvant | Open Active | 2021-05-28 | ECOG-ACRIN EA2174: A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinom |
| ECOG-ACRIN EA2197 | GI Gastric Adjuvant | Open Active | 2021-05-28 | ECOG-ACRIN EA2197: Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial |
| Pharm 012-03 (E7080-G000-318) | GI Hepatic Adjuvant | Open Active | 2022-08-19 | Merck Sharp & Dohme Corp. 012-03 (E7080-G000-318): A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK-3475) in Combination with Transarterial Chemoembolization (TACE) Versus TACE in Participants with Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012) |
| Alliance A021602 | GI Other | Open Active | 2019-05-08 | Alliance A021602: Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus (CABINET) |
| EA2185 | GI Other | Open Active | 2020-07-23 | EA2185: Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs |
| NRG-GI005 | GI Other | Open Active | 2021-06-22 | NRG-GI005: Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA) |
| Pharm SGNTUC-024 | GI Other | Open Active | 2022-01-21 | Seagen Inc. SGNTUC-024: A phase 1b/2 dose escalation and expansion study of tucatinib in combination with trastuzumab and oxaliplatin-based chemotherapy or pembrolizumab-containing combinations for HER2+ gastrointestinal cancers |
| UNM 1603 | GI Other | Open Active | 2016-11-30 | INST UNM 1603: Enhancing Prevention Pathways Toward Tribal Colorectal Health |
| Alliance A021806 | GI Pancreatic Adjuvant | Open Active | 2020-12-08 | Alliance A021806: A Phase III Trial Of Perioperative Versus Adjuvant Chemotherapy For Resectable Pancreatic Cancer |
| ECOG-ACRIN EA2192 | GI Pancreatic Adjuvant | Open Active | 2021-10-04 | ECOG-ACRIN EA2192: APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation |
| SWOG S2104 | GI Pancreatic Adjuvant | Open Active | 2022-03-21 | SWOG S2104: Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumor |
| SWOG S2104 | GI Pancreatic Adjuvant | Open Active | 2022-07-21 | SWOG S2104: Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumor |
| NRG-GU009 | GU Other | Open Active | 2022-04-15 | NRG Oncology NRG-GU009: Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT) |
| NRG-GU010 | GU Prostate Neoadjuvant | Open Active | 2022-03-29 | NRG Oncology NRG-GU010: Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE) |
| Pharm CAAA617C12301 | GU Prostate Advanced | Open Active | 2022-12-05 | Novartis CAAA617C12301: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination with Standard of Care, Versus Standard of Care Alone, in Adult Male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) |
| UNM 1805 | GU Other | Open Active | 2019-01-08 | INST UNM 1805: Trait Mindfulness in Distressed New Mexico Prostate Cancer Survivors |
| NRG-GU011 | GU Other | Open Active | 2022-08-08 | NRG Oncology NRG-GU011: A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean) |
| SWOG S1931 | GU RenalCell Adjuvant | Open Active | 2022-04-29 | SWOG S1931: Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial) |
| Pharm AV-951-20-304 | GU Renal Cell Advanced | Open Active | 2022-07-18 | Aveo Pharmaceuticals, Inc. AV-951-20-304: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line has an Immune Checkpoint Inhibitor |
| Alliance A031704 | GU Renal Cell Advanced | Open Active | 2021-03-29 | Alliance A031704: PD-inhibitor (nivolumab) and Ipilimumab followed by nivolumab vs. VEGF TKI cabozantinib with nivolumab: a phase III trial in metastatic untreated REnal cell cancEr (PDIGREE) |
| GOG-3043 | GYN Cervical Adjuvant | Open Active | 2022-06-29 | GOG Foundation, Inc. GOG-3043: A Randomized Controlled Trial of Robotic Versus Open Radical Hysterectomy for Cervical Cancer (ROCC) |
| ECOG-ACRIN EA8185 | GU Ureter Advanced | Open Active | 2021-09-24 | ECOG-ACRIN EA8185: Phase 2 Study of Bladder-SparIng ChemoradiatioN with Durvalumab in clinical Stage 3, Node PosItive bladdeR cancEr (INSPIRE) |
| Alliance A032001 | GU Ureter Advanced | Open Active | 2023-02-20 | Alliance A032001 MAIN-CAV: Phase III Randomized Trial Of Maintenance Cabozantinib And Avelumab Vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy In Patients With Metastatic Urothelial Cancer |
| Alliance A031901 | GU Ureter Advanced | Open Active | 2021-05-25 | Alliance A031901: Duration Of Immune Checkpoint Therapy In Locally Advanced Or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial |
| Pharm MER-XMT-1536-3 | GYN Other | Open Active | 2022-08-19 | Mersana Therapeutics MER-XMT-1536-3 (GOG-3049): A Phase 3, Randomized, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin as Post-Platinum Maintenance Therapy for Participants with Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) |
| NRG-GY026 | GYN Endometrial Neoadjuvant | Open Active | 2022-11-22 | NRG-GY026: A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab Trastuzumab and Hyaluronidase-Zzfx (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma |
| NRG Oncology NRG-GY012 | GYN Endometrial Advanced | Open Active | 2022-05-23 | NRG Oncology NRG-GY012: A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer |
| NRG-GY025 | GYN Endometrial Adjuvant | Open Active | 2022-05-02 | NRG Oncology NRG-GY025: A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma |
| NRG Oncology NRG-GY006 | GYN Cervical Advanced | Open Active | 2021-08-31 | NRG Oncology NRG-GY006: A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer |
| ECOG-ACRIN EA3161 | Head And Neck Advanced | Open Active | 2021-04-07 | ECOG-ACRIN EA3161: A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA |
| NRG-GY023 | GYN Ovarian Advanced | Open Active | 2022-03-28 | NRG Oncology NRG-GY023: A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab |
| Pharm VS-6766-201;ENGOT-ov60;GOG-3052 | GYN Ovarian Adjuvant | Open Active | 2021-09-23 | Verastem, Inc. VS-6766-201;ENGOT-ov60; GOG-3052: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) |
| UNM 1509 | GYN Other | Open Active | 2020-06-29 | INST UNM 1509: Single Institution (UNM) Prospective Laboratory Study of Cancer and Immune Cells in the Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies |
| INST 1310 | Head And Neck Advanced | Open Active | 2015-02-25 | INST 1310: An Observational, Single-Institution Pilot/Feasibility Study of Exosome Testing as a Screening Modality for Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma |
| ECOG-ACRIN EA3202 | Head And Neck Advanced | Open Active | 2023-03-07 | ECOG-ACRIN EA3202: A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers |
| SWOG S1712 | Hematology Chronic Leukemia | Open Active | 2019-02-21 | SWOG S1712: A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Evidence of Molecular Disease |
| UNM 1512 | Hematology Acute Leukemia | Open Active | 2018-05-23 | INST UNM 1512: A New Drug Discovery Platform using High Throughput Flow Cytometry and a PDX Tissue Repository in AML and MDS |
| RTOG 1216 | Head And Neck Advanced | Open Active | 2021-07-02 | RTOG 1216: Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck |
| NRG-HN009 | Head And Neck Advanced | Open Active | 2022-03-21 | NRG-Oncology NRG-HN009: Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
| ECOG ACRIN EAA181 | Hematology Myeloma | Open Active | 2021-12-17 | ECOG ACRIN EAA181: Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation |
| Pharm EZH-302 | Hematology Lymphoma Non-Hodgkins | Open Active | 2022-06-21 | Epizyme EZH-302: A Phase 1b/3 Double-blind, Randomized, Active-controlled, 3-stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination With Lenalidomide Plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma |
| SWOG S1925 | Hematology Chronic Leukemia | Open Active | 2023-02-03 | SWOG S1925: Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study |
| INST UNM 2105 | Ill Defined | Open Active | 2021-02-05 | INST UNM 2105: Post-Traumatic Stress Disorder in Myeloma and Non-Hodgkins Lymphoma in New Mexico |
| INST UNM 1903 | Hematology Other | Open Active | 2021-06-25 | INST UNM 1903: Collection of Apheresed Leukocytes for Research and Cell Therapy Process Development |
| ECOG-ACRIN NHLBI-MDS | Hematology Other | Open Active | 2020-05-18 | ECOG-ACRIN NHLBI-MDS: THE NATIONAL MDS STUDY A Prospective, Multi-Center Cohort Supporting Research Studies in MDS Natural History |
| SWOG S1803 | Hematology Myeloma | Open Active | 2019-11-14 | SWOG S1803: Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study) |
| ECOG-ACRIN EA5182 | Lung NSCLC Advanced | Open Active | 2021-05-06 | ECOG-ACRIN EA5182: Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) |
| ECOG-ACRIN E4512 | Lung NSCLC Adjuvant | Open Active | 2019-03-01 | ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein |
| Alliance A151216 | Lung NSCLC Adjuvant | Open Active | 2016-05-09 | Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) |
| Alliance A151216 | Lung NSCLC Adjuvant | Open Active | 2016-04-21 | Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) |
| SWOG S1900F | Lung NSCLC Advanced | Open Active | 2022-11-30 | SWOG S1900F: A Randomized Phase II Study of Carboplatin and Pemetrexed w/ or w/o Selpercatinib in Participants With Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study) |
| SWOG S1900E | Lung NSCLC Advanced | Open Active | 2021-08-31 | SWOG S1900E: A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY) |
| SWOG LungMAP | Lung NSCLC Advanced | Open Active | 2019-03-14 | SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study) |
| ECOG-ACRIN EA5191 | Lung NSCLC Advanced | Open Active | 2021-03-26 | ECOG-ACRIN EA5191: A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC |
| NRG Oncology NRG-CC003 | Lung SCLC Adjuvant | Open Active | 2020-08-24 | NRG Oncology NRG-CC003: Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer |
| Alliance A081801 | Lung SCLC Adjuvant | Open Active | 2022-03-15 | Alliance A081801: Integration Of Immunotherapy Into Adjuvant Therapy For Resected NSCLC: ALCHEMIST Chemo-IO |
| Pharm M14-239 | Lung Other | Open Active | 2020-11-16 | AbbVie M14-239: Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer |
| SWOG S1933 | Lung NSCLC Advanced | Open Active | 2021-07-01 | SWOG S1933: A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status |
| SWOG S1914 | Lung NSCLC Advanced | Open Active | 2021-06-29 | SWOG S1914: A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC |
| SWOG S2101 | Solid Tumors Other | Open Active | 2023-03-07 | SWOG S2101: Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Patients With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study |
| SWOG S1823 | Solid Tumors Other | Open Active | 2021-03-26 | SWOG S1823: A Prospective Observational Cohort Study To Assess Mirna 371 For Outcome Prediction In Patients With Newly Diagnosed Germ Cell Tumors |
| ECOG-ACRIN EA6141 | Skin Melanoma Advanced | Open Active | 2021-04-05 | ECOG-ACRIN EA6141: Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma |
| NRG-LU007 | Lung SCLC Advanced | Open Active | 2021-11-16 | NRG-LU007: Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial |
| DCP-001C | Supportive | Open Active | 2016-08-17 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
| DCP-001B | Supportive | Open Active | 2016-08-17 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
| DCP-001A | Supportive | Open Active | 2016-08-17 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
| DCP-001 | Supportive | Open Active | 2016-08-17 | DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP) |
| DCP-002 | Supportive | Open Active | 2017-11-16 | NCI DCP-002: Early Onset Malignancies Initiative (EOMI): Molecular profiling of Breast, Prostate, Colorectal, Liver, Kidney, and Multiple Myeloma among Racially and Ethnically Diverse Populations |
| DCP-001D | Supportive | Open Active | 2016-08-17 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
